Document is current
Any future updates will be listed below
-
Authors
Heo, Dasom https://orcid.org/0000-0003-0482-6822
Kim, Hyunhee https://orcid.org/0000-0003-3241-3638
Katagiri, Wataru
Yoon, Changhan https://orcid.org/0000-0002-6573-2582
Lim, Hae Gyun https://orcid.org/0000-0002-4182-7130
Kim, Chulhong https://orcid.org/0000-0001-7249-1257
Choi, Hak Soo https://orcid.org/0000-0002-7982-6483
Kashiwagi, Satoshi https://orcid.org/0000-0001-8910-3257
Kim, Hyung Ham https://orcid.org/0000-0002-6353-5550
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA280968)
National Heart, Lung, and Blood Institute (R01HL163273)
Ministry of Trade, Industry and Energy (20024916)
Ministry of Science and ICT, South Korea (2022R1A2B5B0200219313)
Ministry of Education (2020R1A6A1A03047902)
- License Information
-
More Information
Article History
Received: 24 June 2024
Revised: 5 November 2024
Accepted: 8 November 2024
First Online: 20 November 2024
Declarations
:
: Hak Soo Choi reports relationships with Nawoo Vision and Ferrex Therapeutics: Consulting, stock, and royalty. Chulhong Kim has a financial interest in OPTICHO; however, he does not support this work. The remaining authors declare that they have no competing financial interests or personal relationships that may have influenced the work reported in this study.
: All animal procedures were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee (protocols #2016N000136 and 2018N000096) and performed under the Public Health Service Policy on Humane Care of Laboratory Animals.
